Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).
Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York.
The portfolio is based on profound knowledge and expertise in liver disease, unique patient-derived model systems and the discovery of a novel, very fundamental mechanism of action underlying these diseases.
Alentis has lead monoclonal antibodies which show consistent compelling efficacy and safety in patient-derived cell and animal models.
Furthermore, Alentis has a proprietary discovery platform enabling fast-track discovery and development of compounds and targets that are relevant in the pathology of late stage liver disease and carcinogenesis.
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas. Through this differentiated platform technology, it’s building a broad pipeline of oral small molecule degraders of extracellular pathogenic proteins.
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). A first compound has recently started clinical development.
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.
Perora brought REDIA to market, the first effective medical food for the dietary management of diabetes type 2.
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.
Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.